Maxwell Skor
Stock Analyst at Morgan Stanley
(2.82)
# 1,671
Out of 5,114 analysts
7
Total ratings
66.67%
Success rate
35.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Overweight | $115 | $67.44 | +70.53% | 1 | Jan 9, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $155.89 | -7.63% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $222.45 | +12.38% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.75 | +152.63% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.06 | +843.40% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.92 | +84.90% | 2 | Nov 20, 2024 |
Monopar Therapeutics
Jan 9, 2026
Initiates: Overweight
Price Target: $115
Current: $67.44
Upside: +70.53%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $155.89
Upside: -7.63%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $222.45
Upside: +12.38%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.75
Upside: +152.63%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.06
Upside: +843.40%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.92
Upside: +84.90%